EMA fast-tracks review of AstraZeneca's sipavibart to stop Covid [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
prophylaxis (preventive treatment) in immunocompromised patients, under an accelerated assessment approach. A long-acting antibody, sipavibart has been designed to neutralise the spike protein interaction with the ACE2 receptor, providing protection from Omicron and other ancestral viral variants. Licensed from RQ Biotechnology in May 2022, the antibody has been developed to safeguard immunocompromised individuals from Covid-19. These patients are at a heightened risk of severe outcomes from the disease. The EMA's Committee for Medicinal Products for Human Use (CHMP) granted sipavibart an accelerated assessment due to its potential for public health and as a therapeutic innovation. The submission for sipavibart is based on the positive outcomes from the Phase III SUPERNOVA clinical trial. This international, double-blind, randomised, placebo-controlled trial analysed the efficacy and safety of sipavibart versus control (tixagevimab/cilgavimab or placebo). The variants of C
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock [Yahoo! Finance]Yahoo! Finance
- AstraZeneca & Aptamer partner to bolster targeted siRNA therapies [Yahoo! Finance]Yahoo! Finance
- AstraZeneca's (AZN) Tagrisso Gets EU Nod for First-Line NSCLC [Yahoo! Finance]Yahoo! Finance
- AstraZeneca's Tagrisso plus chemotherapy wins EU approval for NSCLC [Yahoo! Finance]Yahoo! Finance
- Innovent sells its share in CAR T-cell therapy to IASO Bio for 18% equity [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 7/1/24 - Form 6-K
- 7/1/24 - Form 6-K
- 6/26/24 - Form 11-K
- AZN's page on the SEC website